In contrast, S1R agonists and allosteric modulators have been shown to reduce neuroinflammation levels through the reduction of microglial recruitment and inhibition of pro-inflammatory cytokine production, thereby attenuating gliosis and slowing cognitive impairment from various degenerative conditions, such as chronic epilepsy [108,109,110,111]. The gene discussed is TMBIM4; the disease is Cognitive impairment.